Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2026-03-04 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
天健会计师事务所（特殊普通合伙）关于江苏德源药业股份有限公司2025年年度非经营性资金占用及其他关联资金往来情况的专项审计说明
Audit Report / Information Classification · 95% confidence The document is a specialized audit report titled '非经营性资金占用及其他关联资金往来情况的专项审计说明' (Special Audit Explanation on Non-operating Fund Occupation and Other Related Party Fund Transactions) for the fiscal year 2025. It includes an auditor's opinion, references to Chinese regulatory guidelines for listed companies, and is issued by a certified public accounting firm. The document is 3750 characters long, which is relatively short but contains a full audit opinion and detailed audit scope, not just an announcement or certification. It is not a full annual report (10-K) but a standalone audit report focusing on a specific financial aspect. Therefore, it fits the category of Audit Report / Information (AR). FY 2025
2026-03-04 Chinese
2025年年度报告摘要
Annual Report Classification · 95% confidence The document is titled '年度报告摘要 2025' which translates to 'Annual Report Summary 2025'. It contains detailed financial data for the year 2025, including assets, net profit, earnings per share, and shareholder information. It also includes business descriptions, product lines, R&D activities, and shareholder structure. The document references an audit report with an unqualified opinion, which is typical for annual reports. The length of the document (10,596 characters) and the detailed financial and operational data indicate this is the actual annual report or a substantial summary of it, not just an announcement or a brief summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-03-04 Chinese
关于拟修订《公司章程》公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed amendment to the company's Articles of Association (公司章程) due to a planned profit distribution and capital increase. It includes details about the share capital increase and dividend distribution, and mentions that the amendments will be submitted to the shareholders' meeting for approval. The document is short (863 characters) and does not contain financial statements or detailed financial data. It is not a full report but an announcement of corporate governance changes related to capital structure and company bylaws. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about company governance changes and capital increase plans, not a full Annual Report, Capital Update, or Share Issue announcement. The document also does not meet the threshold for a Share Issue/Capital Change (SHA) filing because it is a notice of proposed amendments pending shareholder approval, not a final capital change announcement.
2026-03-04 Chinese
董事会审计委员会2025年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2025年度履职情况报告" (2025 Annual Performance Report) of the Board Audit Committee of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the committee's activities, meetings, evaluations of external auditors, internal audit guidance, internal control assessments, and overall evaluation for the year 2025. The content focuses on the audit committee's supervisory and evaluative functions rather than presenting standalone audit opinions or accounting principles. It is not a full Annual Report (10-K) or an Audit Report (AR) in the strict sense but rather a report on the audit committee's performance and activities. This type of document aligns best with the category of Audit Report / Information (AR), which includes reports on audit committee activities and audit-related oversight, excluding full annual reports. The document length is 2589 characters, which is sufficient to contain substantive content rather than a mere announcement. Therefore, the classification is AR with high confidence. FY 2025
2026-03-04 Chinese
董事会关于独立董事独立性情况的专项报告
Regulatory Filings Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors. It references regulatory rules about independent directors and assesses their independence based on specific criteria. The document is not an annual report, audit report, or financial statement, nor is it an announcement of voting results or a management change. It is a regulatory compliance report related to governance but does not detail governance structure or compensation. It is a specific regulatory filing about director independence, which fits best under Regulatory Filings (RNS) as it does not fit other categories and is a compliance disclosure.
2026-03-04 Chinese
关于2026年度董事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2026 annual remuneration scheme for the company's directors and senior management. It details the salary standards, applicable period, and approval procedures. It is not a full annual report, audit report, or financial statement, but rather a disclosure about management compensation plans. This fits the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors. The document length is short and focused solely on remuneration, confirming it is not a broader report or announcement of a report publication.
2026-03-04 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.